Testing a pill for large inflamed liver growths
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a daily pill (baricitinib) to shrink large, inflamed liver growths called inflammatory hepatocellular adenomas. It may be an option for people who have at least one growth larger than 5 cm and who are not using estrogen-containing birth control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a specific type of non-cancerous liver growth called an 'inflammatory hepatocellular adenoma' (confirmed by a biopsy).
- At least one of these growths is larger than 5 cm (about the size of a lime).
- You are not currently using birth control that contains estrogen (like some pills or patches).
- You are not pregnant or breastfeeding.
- You are between 18 and 65 years old.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a pill called baricitinib (already used for arthritis) to see if adding it to your HIV medications can help control the virus long-term. You might join if your HIV is well controlled and you are generally healthy.
This trial tests a new drug called BB102 for people with liver cancer (HCC) that has grown after at least one previous treatment. The drug targets a specific protein (FGF19) that may be fueling the cancer, and doctors want to see if it can shrink tumors or slow the disease.
This trial tests a combination of liver-directed chemotherapy (HAIC), an immunotherapy drug (sintilimab), and a drug that blocks blood vessel growth (bevacizumab biosimilar) for advanced liver cancer that hasn't been treated with systemic therapy before. The goal is to see if this triple therapy can shrink or control the cancer.
This trial tests a combination of two treatments—a targeted pill (donafenib) and an immunotherapy drug (pucotenlimab)—along with a type of chemotherapy given directly to the liver through a catheter. The goal is to see if this combination can shrink or control liver cancer better than standard options.
This trial tests baricitinib, an oral medication, for people with intestinal Behçet's disease that hasn't improved with standard treatments. It aims to see if baricitinib can reduce symptoms and help heal gut ulcers.
This study looks at how a new oral drug (called INCB161734) is processed by the body and how safe it is in people with liver problems. It may help doctors understand the right dose for patients with liver impairment.
Hear when a new Inflammatory Hepatocellular Adenoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.